Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Natasha B LeighlMary W RedmanNaiyer RizviFred R HirschPhilip C MackLawrence H SchwartzJames L WadeWilliam J IrvinSreekanth C ReddyJeffrey CrawfordJeffrey D BradleyThomas E StinchcombeSuresh S RamalingamJieling MiaoKatherine MinichielloRoy S HerbstVassiliki A PapadimitrakopoulouKaren KellyDavid R GandaraPublished in: Journal for immunotherapy of cancer (2022)
Durvalumab plus tremelimumab had minimal activity in patients with advanced sqNSCLC progressing on prior anti-PD-1 therapy.Trial registration numberNCT03373760.